Professional Documents
Culture Documents
• DRTB – Common
Anti- TB drugs
Why MULTIDRUGS?
Single drug exposure >>> development of resistance at faster
rate & Chances of relapse.
Combinations produce synergistic effect.
Reduces the duration of chemotherapy (9-12 months).
Faster response ( within few weeks of initiating the therapy)
and symptomatic relief evident within 2-4 weeks.
However, improvement slowly declines as slow multiplying
pathogens respond gradually / slowly.
1.CONVENTIONAL THERAPY
DURING PREGANANCY
2 MONTHS of ISONIAZID+ RIFAMPIN+ PYRIZINAMIDE
followed by
4 MONTHS of ISONAIZID + RIFAMPICIN
FOR BREAST FEEDING MOTHER
SAME AS ABOVE ( MOTHER) + Child immunized with BCG
and isoniazid Prophylaxsis.
IF SENSITIVE/ ALLERGIC
If minor – symptomatic relief- if serious stop the drugs.
Can be restarted with after small challenging dose.
in case of hepatitis ( commonly occurs) – stop – can be
continued later – better to avoid Pyrizinamide.
Fluoroquinolone is a choice over strepto/ ciprofloxacin.
7th semester Chemotherapy of TB 11
CHEMOPROPHYLAXSIS OF TB
When ?
Frequently coming in contact with actual TB patients.
if tested positive for bacilli ( sputum).
TB patient in the family.
Neonate of TB affected mother.
Patients on steroid therapy, diabetic , HIV , Silicosis and leukemic
patient (since prone for opportunistic infections).
Disease inactive - but had received INADEQUATE therapy.
DRUGS used ?
ISONIAZID 300 mg daily for 6-12 months /
ISONIAZID 350mg + RIFAMPIN 700 mg for 6 months.
1. ISONIAZID
EXCELLENT ANTI- TB DRUG and is a part of MDT of TB.
TUBERCULOCIDAL
Kills fast multiplying organism ( cidal) and inhibits the growth of
slowly multiplying pathogens ( static).
MOA: Inhibits the synthesis of MYCOLIC ACID – a unique fatty
acid component of cell wall of TB pathogen. – selectively
acting on that – and not on other gram negative pathogen.
Adverse effects : Dose dependent CNS and hepatotoxicity.
3. PYRAZINAMIDE
Chemically similar to INH.
Weak Tuberculocidal action ( bactericidal) and effective
only in acidic PH.
Highly lethal against intracellularly located pathogen and
in inflammatory sites .
Employed in the intensive therapy part of MDT of TB – the
early part ( 2-3 months) – reduces the duration of therapy
and prevents relapse .
MOA: Similar to INH- Inhibition of Mycolic acid synthesis.
Slowly developing resistance ( since used in combination).
4. ETHAMBUTOL
Selectively tuberculostatic, as effective as streptomycin.
Always as part of MDT of TB.
Helps prevent development of resistance.
MOA: Inhibits ARABINOGALACTAN synthesis and
interferes with the incorporation of Mycolic acid
incorporation into the cell wall of pathogen.
Slowly developing resistance.
5. STREPTOMYCIN
Earliest anti- TB drug to be used.
Tuberculocidal
Used alone – resistance and always as a part of MDT.
Effective against extracellular and rapidly dividing
pathogen.
No more a part of MDT and is substituted with Rifampicin /
Ciprofloxacin.
6. THIOACETAZONE
Relatively weaker
Earlier a part of MDT.
ONLY used as a cost effective
TUBERCULOSTATIC and helps prevent development of
resistance.
6. ETHIONAMIDE
Tuberculostatic.
Moderately effective with short duration of action.( t1/2 =
2-3 hrs).
Resistance develops >>> hardly used now.
7. CYCLOSPORINE
TUBERCULOSTATIC.
Inhibits bacterial wall synthesis by inactivating enzyme
which racemizses L- Alanine and link 2 alanine residues.
Slowly developing resistance.
Part of reserve drug in the MDT of TB.